News
- Author:
- Neil Osterweil
Publish date: June 23, 2017
MADRID – Cerdulatinib is an orally dosed agent that inhibits both the Janus kinase (JAK) 1 and 3 pathways and the spleen tyrosine kinase (SYK) path...
News
- Author:
- Neil Osterweil
Publish date: June 23, 2017
Lugano, Switzerland –
News
- Author:
- Neil Osterweil
Publish date: June 21, 2017
LUGANO, SWITZERLAND – The combination “can be a highly effective and reasonably well-tolerated treatment approach for patients with untreated folli...
News
- Author:
- Neil Osterweil
Publish date: June 21, 2017
“Sequential triple-T” (tailored and targeted treatment) aimed at complete eradication of MRD looks promising for CLL.
News
- Author:
- Neil Osterweil
Publish date: June 20, 2017
LUGANO, SWITZERLAND – Obinutuzumab, a follow-on to rituximab, appeared to be especially useful in combination with lenalidomide among patients who ...
News
- Author:
- Neil Osterweil
Publish date: June 20, 2017
LUGANO, SWITZERLAND –
News
- Author:
- Neil Osterweil
Publish date: June 20, 2017
Umbralisib, a second-generation PI3K inhibitor, appears to have a better safety profile than the first-in-class agent idelalisib.
News
- Author:
- Neil Osterweil
Publish date: June 12, 2017
CHICAGO – CARs just keep getting better, with a new target for multiple myeloma.
News
- Author:
- Neil Osterweil
Publish date: June 12, 2017
CHICAGO –Beyond its role in advanced breast cancer, the antibody-drug conjugate ado-trastuzumab-emtansine (T-DM1; Kadcyla) showed modest activity i...
News
- Author:
- Neil Osterweil
Publish date: June 7, 2017
CHICAGO – In what’s being hailed as practice-changing findings, the anaplastic lymphoma kinase inhibitor alectinib (Alecensa) was associated with m...
Video
- Author:
- Neil Osterweil
Publish date: June 6, 2017
CHICAGO – The standard of care for patients with non–small cell lung cancer positive for the anaplastic lymphoma kinase (ALK) is the ALK inhibitor ...
Video
- Author:
- Neil Osterweil
Publish date: June 6, 2017
CHICAGO – IgG1 agonist monoclonal antibody plus nivolumab induced durable partial responses in patients with tumors thought to be insensitive to im...
News
- Author:
- Neil Osterweil
Publish date: June 5, 2017
CHICAGO – How can we improve responses in heavily pretreated patients with a variety of tumor types?
News
- Author:
- Neil Osterweil
Publish date: June 4, 2017
CHICAGO – The high-intensity method for detecting circulating free DNA (cfDNA) in plasma found at least one significant genetic variant in samples ...
News
- Author:
- Neil Osterweil
Publish date: June 4, 2017
CHICAGO – An online stress management program was associated with significantly better quality of life and lower levels of distress for patients 2 ...
